Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Ptc Therapeutics (PTCT) over the last 13 years, with Q3 2025 value amounting to $203.1 million.

  • Ptc Therapeutics' Receivables - Net rose 154.92% to $203.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $203.1 million, marking a year-over-year increase of 154.92%. This contributed to the annual value of $158.6 million for FY2024, which is 141.03% down from last year.
  • Per Ptc Therapeutics' latest filing, its Receivables - Net stood at $203.1 million for Q3 2025, which was up 154.92% from $196.1 million recorded in Q2 2025.
  • In the past 5 years, Ptc Therapeutics' Receivables - Net registered a high of $210.5 million during Q1 2025, and its lowest value of $78.8 million during Q2 2021.
  • Over the past 5 years, Ptc Therapeutics' median Receivables - Net value was $160.8 million (recorded in 2023), while the average stood at $157.7 million.
  • Its Receivables - Net has fluctuated over the past 5 years, first skyrocketed by 7886.48% in 2021, then tumbled by 208.4% in 2024.
  • Ptc Therapeutics' Receivables - Net (Quarter) stood at $110.5 million in 2021, then soared by 40.88% to $155.6 million in 2022, then grew by 3.35% to $160.8 million in 2023, then dropped by 1.41% to $158.6 million in 2024, then increased by 28.08% to $203.1 million in 2025.
  • Its Receivables - Net stands at $203.1 million for Q3 2025, versus $196.1 million for Q2 2025 and $210.5 million for Q1 2025.